Not surprisingly, there are a lot of questions these days about biosimilars — nearly identical variants of biologic drugs that are expected to achieve the same results in patients as the original brand-name drug. Last week we hosted an hourlong webinar on the biosimilars, and we also fielded many questions on the subject from folks who tuned in.

But we ran out of time to answer all of the questions, so to compensate, we collected some more of those questions and compiled responses below.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy